NCT04444284View on ClinicalTrials.gov

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

May 7, 2021

Study Completion Date

May 7, 2021

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

Investigational RSV vaccine MV-012-968 (Dosage 1)

Single dose administered intranasally on Day 1

BIOLOGICAL

Investigational RSV vaccine MV-012-968 (Dosage 2)

Single dose administered intranasally on Day 1

OTHER

Placebo

Single dose administered intranasally on Day 1

BIOLOGICAL

Investigational RSV vaccine MV-012-968 (Dosage 3)

Single dose administered intranasally on Day 1

Trial Locations (3)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

68134

Meridian Clinical Research, Omaha

68701

Meridian Clinical Research, Norfolk

Sponsors
All Listed Sponsors
lead

Meissa Vaccines, Inc.

INDUSTRY

NCT04444284 - Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children | Biotech Hunter | Biotech Hunter